Neisseria gonorrhoeae (NG) is an important human bacterial pathogen responsible for more than 78 million infections per annum globally 1 . In Australia and elsewhere, NG infection rates are increasing and, critically, antimicrobial resistance (AMR) in NG poses a substantial threat to health security 2 . In response, the Australian Gonococcal Surveillance Programme (AGSP) was established in 1979, and has steadfastly evolved since that time to meet the challenges of continuously emerging AMR ( Figure 1 ).
Effective antibiotic treatment for gonorrhoea is critical for gonococcal disease control, minimising sequelae, reducing HIV transmission 3 , and NG elimination and eradication efforts (theoretically possible as there is no external host). Heightened concerns regarding NG AMR are based on the fact that NG has acquired resistance to all of the antibiotics used as treatment, and has maintained resistance to these various antibiotics even in the absence of selection pressure 4 . The current first line treatment recommended for gonorrhoea in urban Australia, Europe, the United States of America, the United Kingdom, in many countries in the Asia Pacific, and elsewhere, is ceftriaxone and azithromycin.
The addition of azithromycin to ceftriaxone monotherapy in recent years was in response to global trends of increasing ceftriaxone MIC values 5 , increasing reports of treatment failures using ceftriaxone monotherapy, and the emergence of the ceftriaxone resistant strains from Japan in 2010 (the H041 strain) 5 , followed by
France then Spain (the F89 strain) 6, 7 , and then Australia (the A8806 strain) 8 . The move to dual therapy was a speculative bid, without a strong evidence base, to delay and prevent widespread development and expansion of NG AMR to ceftriaxone in the absence of an ideal alternate treatment 5 . Unfortunately with recent reports of increasing azithromycin resistance (detailed below) this particular dual treatment strategy will need review. for treatment which will almost certainly impact on disease burden.
Critically, the report highlighted that data were lacking from countries and areas where disease burden was highest, and information to inform treatment and control strategies is most needed.
Building capacity for surveillance was a primary recommendation of this report, as was the maintenance, enhancement and expansion of existing surveillance systems so as to provide additional evidence to underpin strategies for NG control and to continue to provide data for treatment guidelines. In Focus
